Health3 hrs ago

DRC Ebola Outbreak Death Toll Reaches 80, Minister Cites Up to 50% Lethality

At least 80 people have died in the DRC’s new Ebola outbreak, with nearly 250 suspected cases. Health officials warn the Bundibugyo strain lacks a vaccine and can kill up to half of those infected.

Health & Science Editor

TweetLinkedIn
DRC Ebola Outbreak Death Toll Reaches 80, Minister Cites Up to 50% Lethality
Source: MsfOriginal source

TL;DR: At least 80 deaths and ~250 suspected cases in DRC’s new Ebola outbreak; the Bundibugyo strain has no vaccine and a lethality rate up to 50%.

Context: The outbreak was declared on Friday in Ituri province, which borders Uganda and South Sudan. Health officials traced the first case to a nurse who sought care in Bunia on April 24. By Saturday the death toll had risen to 80, with nearly 250 suspected cases recorded across three health zones.

Key Facts: The DRC health minister said the Bundibugyo strain responsible for the outbreak has no approved vaccine or specific treatment and can reach a lethality rate of up to 50 percent. Only 13 blood samples have been tested at the national lab; eight confirmed Bundibugyo infection, while five were insufficient for analysis. Nearly 250 suspected cases have been reported, with one death also confirmed in neighboring Uganda.

What It Means: Because the strain lacks medical countermeasures, containment relies on rapid isolation, contact tracing, and safe burial practices. Experts note that past Bundibugyo outbreaks have shown lethality ranging from 25 to 50 percent in observational cohort studies, indicating a high risk of death without supportive care. The Africa CDC warns that dense population centers and frequent cross‑border travel could accelerate spread to Uganda and South Sudan.

Practical takeaway: For individuals in the affected area, early reporting of fever or unexplained bleeding and avoiding direct contact with bodily fluids are the most effective preventive steps.

What to watch next: Health authorities will monitor for new cases across borders and assess whether investigational therapeutics or vaccine candidates can be deployed if the outbreak expands.

TweetLinkedIn

More in this thread

Reader notes

Loading comments...